香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 Planetree International Development Limited 梧桐國際發展有限公司 換取認購人的股份 之補充公告 （於百慕達註冊成立的有限公司） （股份代號：613） 有 關 須予披露交易 附屬公司發行新股份 茲提述梧桐國際發展有限公司（「本公司」）日期為二零二五年九月十七日的公告（「該 公告」），內容有關附屬公司發行新股份換取認購人的股份。除另有界定外，本公告 所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供如下有關認購事項之理由及裨益的其他資料。 透過交叉持股創造價值 經本公司董事審閱，交叉持股的潛在裨益如下： – 1 – 1. 利益一致：通過交叉持股，公司之間可共享彼此既得利益。利益一致會促使雙 方採取進一步合作互利行動。 2. 資源共享：認購人與PCL間的交叉持股有助於資源共享，從而大幅節省時間及 成本。透過協同合作，認購人與PCL可實現規模效益，並憑藉對服務供應商 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梧桐國際發展有限公司（於百慕達註冊成立之有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00613 | 說明 | 梧桐國際 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | 本 ...

Core Viewpoint - The stock price of Shenqi Pharmaceutical (600613.SH) experienced a significant decline, dropping over 5% after the company was implicated in financial fraud by the Shanghai Securities Regulatory Bureau [2][3]. Financial Misconduct - Shenqi Pharmaceutical was found to have misappropriated sales expenses amounting to 44.83 million yuan through a discontinued "basic drug promotion plan" and fabricated accounts receivable by transferring funds through employee personal accounts [4]. - This fraudulent activity led to the company reversing credit impairment provisions of 44.83 million yuan, resulting in discrepancies in the 2023 annual report [5]. Financial Performance - In 2023, Shenqi Pharmaceutical reported a revenue of 2.341 billion yuan, a year-on-year decrease of 2%, while the net profit attributable to shareholders was 57 million yuan, reflecting a year-on-year increase of 17.41% [7]. - For the first half of 2025, the company achieved a revenue of 961 million yuan, a year-on-year decline of 13.47%, and a net profit of 32.81 million yuan, down 13.29% compared to the previous year [8]. Regulatory Actions - The Shanghai Securities Regulatory Bureau imposed corrective administrative measures on Shenqi Pharmaceutical, issuing warning letters to the then Chairman Zhang Taotao, General Manager Feng Bin, and Chief Financial Officer Chen Zhimian due to the irregularities in accounts receivable handling [7]. - The company has committed to rectifying the issues and submitting a corrective report within the stipulated timeframe to prevent future occurrences [7]. Company Background - Founded in 1983, Shenqi Pharmaceutical specializes in the research, production, and sales of pharmaceuticals, with products covering various therapeutic areas including oncology, respiratory, cardiovascular, and gynecological treatments [7].

(Incorporated in Bermuda with limited liability) （ 於 百 慕 達 註 冊 成 立 的 有 限 公 司 ） (Stock code 股份代號：613) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-Registered Holder (Note 1), Planetree International Development Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") 各位非登記持有人 （附註1） ： 梧桐國際發展有限公司（「本公司」） －刊發2025年中期報告（「本次公司通訊」）之發佈通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站www.planetreeintl.com及香港聯合交易所有限公司（「聯交所」）之網站www.hkexnews.hk（「網站版本」）。本公司 建議 閣下閱覽本公司本次公司通訊的網站版本。 ...

(Incorporated in Bermuda with limited liability) （ 於 百 慕 達 註 冊 成 立 的 有 限 公 司 ） (Stock code 股份代號：613) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholder(s), Planetree International Development Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.planetreeintl.com and the website of The Stock Exchange o ...

Financial Performance - Total revenue for the six months ended June 30, 2025, was approximately HKD 45.3 million, a decrease of about HKD 8.1 million or 15.2% compared to the same period in 2024[5] - The group recorded a consolidated profit before tax of approximately HKD 104.6 million, compared to a loss of approximately HKD 94.2 million in 2024[5] - Profit attributable to shareholders for the period was approximately HKD 107.7 million, compared to a loss of approximately HKD 91.1 million in the previous year[5] - The group achieved other comprehensive income of approximately HKD 35.1 million, compared to an expense of approximately HKD 67.3 million in 2024[6] - Financial services revenue, including other financial services, totaled approximately HKD 19,700,000, down from HKD 46,200,000 in the previous year[22] - The tactical and strategic investment segment generated a profit of approximately HKD 140,400,000, a significant improvement from a loss of HKD 88,200,000 in the previous year[19] - The company reported a significant recovery in impairment losses, with a reversal of HKD 36,470,000 for margin loans compared to a loss of HKD 15,636,000 in the previous year[58] - The company reported a net profit attributable to shareholders of HKD 107,663,000 for the six months ended June 30, 2025, compared to a loss of HKD 91,050,000 in the same period of 2024[85] Revenue Sources - Interest income from margin loans decreased to approximately HKD 6 million, down from approximately HKD 35.6 million in 2024, due to a reduction in margin loan interest rates from 8% to 2%[12] - Revenue from the securities and futures advisory services increased to approximately HKD 3.6 million, up from approximately HKD 1.8 million in 2024, driven by increased demand for financial advisory services[12] - Revenue from credit and lending services increased from approximately HKD 1.6 million to approximately HKD 2.3 million, primarily due to an increase in loans during the period[15] Assets and Liabilities - As of June 30, 2025, the company's unaudited net asset value was approximately HKD 1,762,400,000, an increase of about HKD 165,500,000 from the end of the previous fiscal year[24] - The company's total assets increased to HKD 1,076,952,000 from HKD 1,007,147,000, reflecting a growth of 6.9%[60] - Total liabilities as of June 30, 2025, were HKD 290,680,000, compared to HKD 269,424,000 in the previous year, reflecting an increase of approximately 7.8%[74] - The total amount of personal and corporate loans and interest receivable was approximately HKD 233,362,000, with a net amount of HKD 232,782,000 after impairment losses[91] Shareholder Information - As of June 30, 2025, major shareholders included Ms. Luo Qiyin, holding 628,263,640 shares, representing approximately 65.41% of the total issued share capital[50] - Future Capital Group Limited, wholly owned by Ms. Luo Qiyin, also holds 628,263,640 shares, equating to 65.41% of the total issued share capital[51] Corporate Governance and Compliance - The group has complied with all corporate governance codes as outlined in the Listing Rules during the reporting period[39] - The group has no outstanding stock options or share awards as of the reporting period[43] Strategic Initiatives - The company plans to strengthen its integrated financial services system and expand into innovative technology-driven financial services, including cryptocurrency financing and trading[20] - The company anticipates expanding its business opportunities into the artificial intelligence chip and semiconductor sectors through the acquisition of Warpdrive[102] Employee and Management Information - The group has a total of 36 employees, including all directors, as of June 30, 2025[38] - The total compensation for key management personnel was HKD 2,387,000 for the first half of 2025, a decrease of 5.9% from HKD 2,537,000 in the same period of 2024[104] Investment Activities - The company completed the acquisition of Warpdrive Technology Limited for a total consideration of HKD 29,850,000, funded by the issuance of 15,000,000 shares at HKD 1.99 per share[102] - The company acquired an additional 9.9% stake in Genius Spring Limited for HKD 3,800,000, increasing its ownership to 100%[61] Impairment and Provisions - The company has appointed independent professional valuers to assess impairment on outstanding loans, with provisions of approximately HKD 600,000 as of June 30, 2025, compared to HKD 2,000,000 the previous year[16] - The company recognized a provision for impairment losses of HKD 1,045,000 for trade receivables related to corporate advisory services as of June 30, 2025, unchanged from December 31, 2024[89] Fair Value Measurements - The fair value of investment properties decreased from HKD 407.5 million as of December 31, 2024, to HKD 340.5 million as of June 30, 2025, representing a reduction of HKD 67 million[109] - The company utilized independent qualified valuers for the fair value assessment of investment properties, ensuring accuracy in the valuation process[109]

Core Viewpoint - Haotian International Investment (01341) experienced a significant stock price increase, rising over 13% towards the end of trading, with a current price of 0.255 HKD and a trading volume of 1.82 billion HKD [1] Group 1: Company Actions - Wutong International (00613) announced that its wholly-owned subsidiary PCL will issue 850 new shares to Haotian International Investment for a total consideration of 400 million HKD [1] - Haotian International Investment will pay for this issuance by issuing 1.6 billion shares, resulting in Wutong International holding 14.8% of Haotian International Investment's equity, making it a major shareholder [1] - Following this transaction, Wutong International's stake in PCL will be diluted from 100% to 70.2%, with PCL being an indirect non-wholly owned subsidiary of Wutong International [1] Group 2: Strategic Implications - Haotian International Investment believes that the subscription will benefit its further development in the financial services sector, leveraging PCL's expertise, resources, and market network [1] - The subscription will establish a strategic alliance between the companies, creating synergies in the sharing of expertise and resources within the financial services industry [1]

Core Viewpoint - Haotian International Investment (01341) experienced a significant stock price increase, rising over 13% towards the end of trading, with a current price of 0.255 HKD and a trading volume of 1.82 billion HKD [1] Group 1: Company Actions - Wutong International (00613) announced that its wholly-owned subsidiary PCL will issue 850 new shares to Haotian International Investment for a total consideration of 400 million HKD [1] - Following the issuance, Wutong International will hold 14.8% of Haotian International Investment's equity, making it a major shareholder, while its stake in PCL will be diluted from 100% to 70.2% [1] Group 2: Strategic Implications - The subscription is expected to benefit Haotian International Investment's further development in the financial services sector, leveraging PCL's expertise, resources, and market network [1] - The transaction will establish a strategic alliance between the companies, creating synergies in the sharing of professional knowledge and resources within the financial services industry [1]

Core Viewpoint - Haotian International Investment plans to issue 1.6 billion shares at HKD 0.25 per share, representing a discount of approximately 7.41% from the closing price, to acquire shares in PCL, a subsidiary of Wutong International [1] Group 1 - The total value of the share issuance is HKD 400 million, aimed at subscribing to PCL shares [1] - The company believes this acquisition will benefit its financial services business and establish a strategic alliance with PCL for resource sharing and business collaboration [1] - The collaboration is expected to enhance Haotian International Investment's net asset value per share and create more market opportunities, promoting long-term sustainable growth [1]

Group 1 - The company, Haotian International Investment (01341), has entered into a subscription agreement with PCL to subscribe for HKD 400 million worth of shares, equating to 850 shares of PCL, with a settlement through the issuance of 1.6 billion consideration shares at a price of HKD 0.25 per share, representing a discount of approximately 7.41% compared to the closing price of HKD 0.270 on that day [1] - PCL is an indirect non-wholly owned subsidiary of Wutong International (00613) and serves as a holding company for all licensed activities regulated by the Securities and Futures Commission [1] Group 2 - The subscription is expected to benefit the company's financial services development due to PCL's expertise, resources, and market network in the financial services industry [2] - The strategic alliance formed through the subscription will create synergies in sharing professional knowledge and resources, identifying and implementing joint projects, exchanging business opportunities, and sharing market intelligence for business development and risk management [2] - The subscription is anticipated to enhance the company's net asset value per share and provide more market opportunities, driving long-term sustainable growth [2]